Showing 201-210 of 9106 results for "".
Next Generation Environmental Protection: Antioxidants and Chelators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/next-generation-environmental-protection-antioxidants-and-chelators/23802/As understanding of the pathogenesis of skin aging and carcinogenesis evolves, so do topical protective strategies.What Should Dermatology PAs Know About Training and Onboarding
https://practicaldermatology.com/videos/pa-perspectives/what-should-dermatology-pas-know-about-training-and-onboarding/24395/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses what realistic expectations PAs should have while training and onboarding in a new practice. Topics include what new PAs should expect at 30, 60, and 90 daysPA Perspectives - Building a Schedule
https://practicaldermatology.com/series/pa-perspectives/pa-perspectives-building-schedule/24488/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, provides insights on what a PA should be providing to an MD and their office staff. He also discusses realistic expectations for a new PA regarding scheduling, and givPASI-HD: New Method for Measuring Severity in Mild to Moderate Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/pasi-hd-new-method-for-measuring-severity-in-mild-to-moderate-plaque-psoriasis/20185/Robert Higham, MPAS, PA-C, Executive Director of Clinical Development of Arcutis Biotherapeutics, discusses PASI-HD, a new measure designed to assess severity and therapeutic response in patients with mild and moderate psoriasis. PASI High Discrimination (PASI-HD) was developed to better understandClascoterone: A Novel Topical Anti-androgen for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/clascoterone-a-novel-topical-anti-androgen-for-the-treatment-of-acne/23133/For the first time in almost 15 years, a new chemical entity may be coming to the market for the topical treatment of acne vulgaris.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.A Review of Complications of Biologic Therapy for Psoriasis
https://practicaldermatology.com/topics/general-topics/1109_02-php/22053/Therapeutic success requires clinicians to understand emerging and established safety concerns.Impetigo: An Unconventional Case Report
https://practicaldermatology.com/topics/rare-disease/impetigo-an-unconventional-case-report/26246/Mauri Hart, a medical student at the Oklahoma State University College of Osteopathic Medicine, takes a look at a unique case study, and tests the reader's knowledge of impetigo.Hyperpigmentation in Darker Skin Types: A Review of Current Treatments
https://practicaldermatology.com/programs/practical-dermatology/hyperpigmentation-in-darker-skin-types-a-review-of-current-treatments/24217/Pigmentary disorders are a leading concern for patients and consumers worldwide.Acne Management Today: Exploring the Role of Topical Adapalene in OTC Care
https://practicaldermatology.com/topics/acne-rosacea/acne-management-today-exploring-the-role-of-topical-adapalene-in-otc-care/23205/La Roche-Posay’s EFFACLAR Adapalene 0.1% Gel provides effective OTC care for acne.